Latest News

July 10, 2018

Pionyr Immunotherapeutics and ProBioGen Initiate a Second Immuno-Oncology Contract Development and Manufacturing Project View press release

December 13, 2017

Pionyr Immunotherapeutics Completes $62 million Series B Financing to Advance Antibody-Based Therapeutics Targeting the Tumor Microenvironment Read more

November 6, 2017

Pionyr Immunotherapeutics Appears in BioCentury View article

January 4, 2017

Pionyr Immunotherapeutics Closes Financing with Focus on Developing Antibody-based Immuno-oncology Therapeutics Read more